arrow
Return

Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity

delete2022-09-15
delete21
delete
OA
AI
T
Thomas C. Westbrook
X
Xiangnan Guan
E
Eva S. Rodansky
D
Diana Flores
C
Chia-Jen Liu
A
Aaron M. Udager
R
Radhika A. Patel
M
Michael C. Haffner
Y
Ya‐Mei Hu
D
Duanchen Sun
T
Tomasz M. Beer
A
Adam Foye
R
Rahul Aggarwal
D
David A. Quigley
J
Jack Youngren
C
Charles J. Ryan
M
Martin Gleave
Y
Yuzhuo Wang
J
Jiaoti Huang
I
Ilsa M. Coleman
C
Colm Morrissey
P
Peter S. Nelson
C
Christopher P. Evans
P
Primo N. Lara
R
Robert E. Reiter
O
Owen N. Witte
M
Matthew B. Rettig
C
Christopher K. Wong
A
Alana S. Weinstein
U
Uzunangelov, Vlado
J
Joshua M. Stuart
G
George Thomas
F
Felix Y. Feng
E
Eric J. Small
J
Joel A. Yates
Z
Zheng Xia *
J
Joshi J. Alumkal *
DOI:10.1038/s41467-022-32701-6delete
deleteOriginal
deleteShare
deleteSave
View PDF
Abstract

Abstract

En 中文
The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent enza clinical resistance mechanisms have been described, including lineage plasticity in which the tumors manifest reduced dependency on the AR. To improve our understanding of enza resistance, herein we analyze the transcriptomes of matched biopsies from men with metastatic CRPC obtained prior to treatment and at progression (n = 21). RNA-sequencing analysis demonstrates that enza does not induce marked, sustained changes in the tumor transcriptome in most patients. However, three patients' progression biopsies show evidence of lineage plasticity. The transcription factor E2F1 and pathways linked to tumor stemness are highly activated in baseline biopsies from patients whose tumors undergo lineage plasticity. We find a gene signature enriched in these baseline biopsies that is strongly associated with poor survival in independent patient cohorts and with risk of castration-induced lineage plasticity in patient-derived xenograft models, suggesting that tumors harboring this gene expression program may be at particular risk for resistance mediated by lineage plasticity and poor outcomes. Lineage plasticity is increasingly recognized as an emergent resistance mechanism after treatment with androgen receptor signalling inhibitors. To understand determinants of resistance, the authors analyzed the transcriptomes of patient tumor biopsies before enzalutamide treatment and at progression and identified a gene expression program associated with lineage plasticity risk and poor outcomes.
Keywords:
RESISTANT PROSTATE-CANCER
ABIRATERONE ACETATE
ANTIANDROGEN
BICALUTAMIDE
MECHANISMS
GENE
AI Summary

AI Summary

Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.

Journal

Nature Communications cover
Nature Communications
IF:
15.7
Papers:
9.2W
Citations:
91.2W

Organization

U
university of california san francisco
Scholars:
5.2W
Papers: 4.0W
Citations: 67
U
University of Minnesota Twin Cities
Scholars:
3.7W
Papers: 3.1W
Citations: 58
F
Fred Hutchinson Cancer Center
Scholars:
1.2W
Papers: 9.3K
Citations: 18
University of California System cover
University of California System
Scholars:
37.2W
Papers: 33.6W
Citations: 6.6K
O
Oregon Health & Science University
Scholars:
2.5W
Papers: 2.1W
Citations: 39
U
University of Michigan
Scholars:
6.4W
Papers: 5.3W
Citations: 124
U
ucsf medical center
Scholars:
2.3K
Papers: 1.8K
Citations: 5
U
university of michigan system
Scholars:
9.0W
Papers: 8.6W
Citations: 133
U
University of British Columbia
Scholars:
6.9W
Papers: 6.1W
Citations: 8.6W
researcher View more organizations